HEPTA Medical

What HEPTA Medical does

HEPTA Medical is a France-based medical device developer founded in 2019 and headquartered at the DocCity innovation center in Suresnes, a suburb of Paris. The company is building a next-generation microwave ablation platform intended for early-stage cancer treatment, with a stated focus on enabling more precise and controllable tumor ablation procedures in hospital and clinical settings.

The company's core product is a microwave ablation platform that integrates a patented in-situ tissue temperature sensor with proprietary predictive software. The architecture is designed to provide real-time monitoring and control of ablation procedures, addressing the clinical challenge of ensuring complete tumor destruction while minimizing damage to surrounding healthy tissue. The company's stated value proposition centers on improved safety, efficacy, and procedure predictability relative to conventional microwave ablation systems, and it holds a documented competitive advantage around the combination of its patented sensor and its predictive software layer.

HEPTA Medical is privately held, employs 1–10 people, and has raised approximately $6.3 million across two funding rounds — an initial seed from MD Start in 2019 and a 2024 round led by Bpifrance with participation from Cléry and M&L Healthcare Investments. The company has Thomas Bancel as CEO and operates with a horizontal go-to-market targeting healthcare providers and hospitals performing tumor ablation. No pricing, distribution, or commercial revenue data is publicly disclosed, and the firm appears to be in a pre-commercial development phase pending regulatory milestones.

Name

HEPTA Medical

Legal name

HEPTA MEDICAL

Website

https://heptamed.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

HEPTA Medical is a France-based medical device company developing a microwave ablation platform with a patented in-situ tissue temperature sensor and proprietary predictive software for real-time monitoring of early-stage cancer treatments in hospital settings.

Ownership category

akta.pro rank

Product category

Medical Devices - Microwave Ablation Systems

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)

Keywords

• Microwave ablation
• Medical devices
• Tumor ablation
• Cancer treatment
• Tissue temperature monitoring

Headquarters

HQ city

Suresnes

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain

Core offering

HEPTA Medical develops a microwave ablation platform integrating an in-situ patented tissue temperature sensor. Combined with proprietary predictive software, the technology enables real-time monitoring and control of microwave ablation procedures for early-stage cancer treatments.

Product overview

HEPTA Medical offers a single unified product: a microwave ablation platform that combines hardware (microwave ablation device with in-situ patented tissue temperature sensor) with proprietary predictive software. The platform enables real-time monitoring and control of ablation procedures. The technology is designed for medical microwave ablation applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Microwave Ablation Platform

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature1 record

Recent moves3 records

Expansion highlights2 records

Direct peers

• Medtronic: Medtronic's Emprint and Emprint HP are FDA-cleared microwave ablation systems widely used for soft tissue tumor ablation. Directly comparable to HEPTA in modality (microwave), target indication (tumor ablation), and customer base (interventional radiologists, hospitals), though Medtronic operates at vastly larger scale with a multi-product oncology portfolio.
• AngioDynamics: AngioDynamics offers the Solero microwave ablation system for tumor treatment, directly competing with HEPTA in modality, clinical use case, and customer. As a focused oncology/interventional player, it is a closer commercial analog than diversified medtech majors and a benchmark for HEPTA's commercial scale-up trajectory.
• Emblation Microwave: Emblation is a UK-based medical microwave ablation company developing compact systems for clinical use. It is a small, focused peer similar to HEPTA in stage, modality, and approach to bringing microwave ablation to specific clinical niches (initially dermatology and oncology).

Broad incumbents

• Johnson & Johnson (Ethicon): Ethicon (a J&J subsidiary) markets the Neuwave microwave ablation system and broader interventional oncology portfolio. It competes head-to-head with HEPTA's microwave ablation platform while also offering surgical and energy-based device alternatives across many specialties, giving it the scale to bundle, discount, and outpace smaller entrants.
• Boston Scientific: Boston Scientific has a broad interventional oncology and surgical ablation portfolio (including RF and microwave platforms) and competes with HEPTA across multiple tumor ablation use cases. Its size, salesforce, and global distribution create the dominant incumbent benchmark HEPTA must differentiate against.
• Varian (Siemens Healthineers): Varian, now part of Siemens Healthineers, is a leader in radiation oncology and interventional oncology workflows. While primarily radiation-therapy focused, it increasingly integrates ablation and image-guided interventional oncology, competing for the same interventional radiology budgets and tumor-treatment patient pathways as HEPTA.
• Terumo: Terumo has a substantial interventional oncology and ablation business through its MicroVention and legacy Terumo Interventional Systems units, with microwave and RF ablation products. Comparable to HEPTA in target use case and customer, though Terumo's portfolio is vastly broader across vascular and interventional care.

Emerging players

• Creo Medical: Creo Medical develops advanced energy-based endoscopic and laparoscopic ablation platforms (Speedboat, MicroBlate) including microwave ablation for GI and lung lesions. Comparable to HEPTA as a smaller, innovation-led energy/ablation company targeting differentiated procedure outcomes rather than commodity hardware.
• Mermaid Medical: Mermaid Medical is a European interventional oncology and radiology distributor/manufacturer offering ablation systems (including microwave). Comparable to HEPTA in regional focus and customer overlap, and a potential commercialization or distribution pathway peer.

Others

• Perspectum: Perspectum builds image-based diagnostic and treatment-planning software for liver and oncology applications. It is not a direct ablation competitor but is thematically adjacent to HEPTA's predictive-software-for-treatment approach and represents the kind of software-driven oncology decision-support peer that HEPTA could partner with or compete against.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat1 record

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/hepta-medical

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HEPTA Medical